Education
About Us
Working with TipRanks
Follow Us
Mersana Therapeutics Inc (MRSN)
NASDAQ:MRSN
MRSN Stock Chart & Stats
$27.52
-$0.05(-3.28%)
At close: 4:00 PM EST
$27.52
-$0.05(-3.28%)
Day’s Range― - ―
52-Week Range$5.21 - $70.73
Previous CloseN/A
Volume429.52K
Average Volume (3M)61.87K
Market Cap
$40.72M
Enterprise Value-$19.93M
Total Cash (Recent Filing)$56.39M
Total Debt (Recent Filing)$2.29M
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Mar 04, 2026EPS Estimate
-3.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding4,990,692
10 Day Avg. Volume95,463
30 Day Avg. Volume61,865
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-18.43
Price to Sales (P/S)4.33
P/FCF Ratio-2.12
Enterprise Value/Market Cap-0.49
Enterprise Value/Revenue-0.60
Enterprise Value/Gross Profit-0.61
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$30.75Price Target Upside11.74% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition ImpactMersana has been acquired for a 182% premium over its previous closing price, indicating a significant valuation boost.
Financial PerformanceThe net loss reported was better than consensus estimates of a loss of $8.3 million, or a loss of $1.54 per share.
Regulatory MilestonesBreakthrough Therapy Designation for ACC was granted by the FDA, which adds credibility to the development efforts.
Bears Say
Financial ChallengesThe book value per share is reported as negative, indicating financial challenges for the company.
Market SentimentShort interest is at 10.6% of float, indicating some market skepticism about the stock.
Profitability ConcernsReturn on Equity is significantly negative, suggesting the company is currently not generating profit from its equity.
Mersana Therapeutics News
MRSN FAQ
What was Mersana Therapeutics Inc’s price range in the past 12 months?
Mersana Therapeutics Inc lowest stock price was $5.21 and its highest was $70.72 in the past 12 months.
What is Mersana Therapeutics Inc’s market cap?
Mersana Therapeutics Inc’s market cap is $40.72M.
When is Mersana Therapeutics Inc’s upcoming earnings report date?
Mersana Therapeutics Inc’s upcoming earnings report date is Mar 04, 2026 which is in 90 days.
How were Mersana Therapeutics Inc’s earnings last quarter?
Mersana Therapeutics Inc released its earnings results on Nov 14, 2025. The company reported -$1.51 earnings per share for the quarter, missing the consensus estimate of -$1.131 by -$0.379.
Is Mersana Therapeutics Inc overvalued?
According to Wall Street analysts Mersana Therapeutics Inc’s price is currently Undervalued.
Does Mersana Therapeutics Inc pay dividends?
Mersana Therapeutics Inc does not currently pay dividends.
What is Mersana Therapeutics Inc’s EPS estimate?
Mersana Therapeutics Inc’s EPS estimate is -3.05.
How many shares outstanding does Mersana Therapeutics Inc have?
Mersana Therapeutics Inc has 4,990,692 shares outstanding.
What happened to Mersana Therapeutics Inc’s price movement after its last earnings report?
Mersana Therapeutics Inc reported an EPS of -$1.51 in its last earnings report, missing expectations of -$1.131. Following the earnings report the stock price went up 1.786%.
Which hedge fund is a major shareholder of Mersana Therapeutics Inc?
Currently, no hedge funds are holding shares in MRSN
Mersana Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$30.75 (11.74% Upside)
$30.75 (11.74% Upside)
Hedge Fund Trend
Decreased
By 17.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-52.79%
Trailing 12-Months
Company Description
Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
MRSN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in clinical trials and milestone achievements, especially in the Emi-Le and XMT-2056 programs. However, challenges remain with proteinuria management and modest revenue growth, balanced by a stable financial outlook.View all MRSN earnings summariesMRSN Stock 12 Month Forecast
Average Price Target
$30.75
▲(11.74% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Grace Therapeutics
―
BioAtla
―
LAVA Therapeutics
―
Senti Biosciences
―
Ownership Overview
Currently, No data available
---